Ipsen SA (IPSEF) reports robust financial performance with a 9.9% sales increase and strategic pipeline developments, despite ...

Ipsen expects total sales growth of more than 5% at constant exchange rates in 2025, supported by the continued expansion of products like IQIRVO, ONIVYDE, and Bylvay. However, Somatuline faces ...

Investing.com -- Shares of Ipsen (EPA: IPN) dropped 2.7% as the market reacted to the company's mixed fourth-quarter results.

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...

In a report released on February 11, Justine Telliez from Kepler Capital maintained a Hold rating on Ipsen (0MH6 – Research Report), with a ...

Morgan Stanley (NYSE:MS) analysts adjusted their stance on Ipsen SA (EPA:IPN:FP) (OTC: IPSEF), downgrading the stock from Equalweight to Underweight. The firm also set a new price target of EUR120.00 ...

French drugmaker Ipsen today released final results from the Phase III CheckMate -9ER trial of Cabometyx (cabozantinib) in ...

A former executive of a global pharmaceutical company in Boston was sentenced Thursday for earning more than $250,000 through insider trading, the U.S. Attorney said.

A former executive at French drugmaker Ipsen was sentenced on Thursday to two months in a U.S. prison for illegally trading ...

Infant mortality in the U.S. has increased by 7% since the 2022 Dobbs v. Jackson U.S. Supreme Court decision overturned the ...

In a report released today, Lucy Codrington from Jefferies maintained a Hold rating on Ipsen (0MH6 – Research Report), with a price target of ...